 Nasopharyngeal carcinoma NPC is endemic in Southern China and Southeast Asia. For locoregionally advanced NPC,especially for the high risk NPC EB virus DNA 4000 copiesml ,the incidence of treatment failure is still high. Although concurrent chemoradiotherapy CCRT can improve the treatment outcomes of these patients, approximately 25 of locoregionally advanced NPCs relapse. Adjuvant chemotherapy or inducing chemotherapy addition to CCRT did not significantly improve patient survival compared to CCRT alone. Hence, there is an urgent need for novel therapies to improve disease-free survival and reduce treatment-related toxicity in patients. 